Form 4: Adaptimmune Therapeutics CEO Acquires Options to Purchase Over 8.5 Million Ordinary Shares

Adaptimmune Therapeutics' CEO, Adrian Rawcliffe, reports the acquisition of options to purchase over 8.5 million ordinary shares in the company.

Summary

• Adrian Rawcliffe, CEO of Adaptimmune Therapeutics PLC, filed a Form 4 detailing changes in beneficial ownership.
• The report indicates the acquisition of options to purchase 5,143,248 ordinary shares at an exercise price of $0.1 and 3,428,832 ordinary shares at an exercise price of $0.0013 on February 20, 2025.
• The options are exercisable in installments starting February 20, 2026, with varying schedules for each tranche.
• The filing also confirms that Rawcliffe directly owns 5,143,248 and 3,428,832 ordinary shares through these options.
• The exercise prices were converted from GBP amounts based on an exchange rate of U.S.$ 1.257137 to GBP1.00.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard filing related to option grants. The CEO taking options is generally a positive sign, but the filing itself is simply a procedural disclosure.

Positives

• The CEO's acquisition of options may signal confidence in the company's future performance.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track management's alignment with shareholder interests.

Stakeholder Impact

• The acquisition of options by the CEO could be viewed positively by shareholders, as it aligns management's interests with the company's performance.

Key Dates